A detailed history of Royal Bank Of Canada transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 8,565 shares of KURA stock, worth $92,502. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,565
Previous 7,070 21.15%
Holding current value
$92,502
Previous $145,000 15.17%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.57 - $23.23 $27,762 - $34,728
1,495 Added 21.15%
8,565 $167,000
Q2 2024

Aug 14, 2024

BUY
$17.53 - $22.98 $89,613 - $117,473
5,112 Added 261.08%
7,070 $145,000
Q1 2024

Nov 05, 2024

SELL
$13.42 - $23.53 $68,603 - $120,285
-5,112 Reduced 72.31%
1,958 $41,000
Q1 2024

May 15, 2024

SELL
$13.42 - $23.53 $252,497 - $442,716
-18,815 Reduced 90.57%
1,958 $41,000
Q4 2023

Feb 14, 2024

BUY
$7.58 - $14.38 $67,621 - $128,283
8,921 Added 75.27%
20,773 $298,000
Q3 2023

Nov 14, 2023

BUY
$8.44 - $11.86 $42,630 - $59,904
5,051 Added 74.27%
11,852 $108,000
Q2 2023

Aug 14, 2023

BUY
$9.62 - $13.99 $29,369 - $42,711
3,053 Added 81.46%
6,801 $71,000
Q1 2023

May 15, 2023

SELL
$10.71 - $14.6 $151,128 - $206,020
-14,111 Reduced 79.01%
3,748 $45,000
Q4 2022

Feb 14, 2023

BUY
$11.23 - $16.9 $188,798 - $284,122
16,812 Added 1605.73%
17,859 $221,000
Q3 2022

Nov 14, 2022

BUY
$12.01 - $19.45 $7,085 - $11,475
590 Added 129.1%
1,047 $14,000
Q2 2022

Aug 15, 2022

SELL
$10.71 - $18.33 $37,817 - $64,723
-3,531 Reduced 88.54%
457 $9,000
Q1 2022

May 16, 2022

SELL
$11.78 - $16.98 $97,432 - $140,441
-8,271 Reduced 67.47%
3,988 $64,000
Q4 2021

Feb 14, 2022

BUY
$12.22 - $19.57 $65,560 - $104,993
5,365 Added 77.82%
12,259 $172,000
Q3 2021

Nov 15, 2021

BUY
$15.42 - $21.72 $38,349 - $54,017
2,487 Added 56.43%
6,894 $129,000
Q2 2021

Aug 16, 2021

BUY
$20.85 - $29.88 $91,885 - $131,681
4,407 New
4,407 $92,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $722M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.